巴西圣保罗州：中国科兴公司新冠疫苗具备有效性

Gustavo Romero, professor at the University of Brasilia and coordinating doctor for tests of the Sinovac Biotech vaccine, shows the vaccine to journalists amidst the COVID-19 pandemic at the University Hospital, Brasilia, Brazil, August 5, 2020. /CFP

当地时间23日，巴西圣保罗州政府和布坦坦研究所举行新闻发布会宣布，北京科兴中维生物技术有限公司研发的克尔来福新冠疫苗（CoronaVac）具备有效性。这意味着巴西卫生监管机构可以授权批准这款疫苗的使用。

Clinical trials of CoronaVac, coronavirus vaccine developed by Chinese biopharmaceutical company Sinovac Biotech, have "reached the efficacy threshold" which is 50 percent, demanded by the World Health Organization (WHO), the Brazilian institute charged with its production and distribution said on Wednesday. 

在发布会上，布坦坦研究所所长迪马斯·科瓦斯（Dimas Covas）表示——

“我们昨天收到了疫苗试验的有效性数据。疫苗的有效性超过了在巴西和在中国申请紧急使用所需达到的下限。我们非常激动。对于巴西科学界来说，这是历史性的一天，也是为巴西民众带来希望的一天。”

他预计，对疫苗试验结果的进一步分析将在15天后完成。

Butantan Institute Director Dimas Covas said the vaccine has reached the efficacy threshold that allowed them to seek an emergency use authorization from Brazil's Anvisa regulatory agency. The WHO's efficacy threshold is 50 percent.

克尔来福新冠疫苗的三期临床试验在巴西、印度尼西亚、土耳其和智利四国展开。公开信息显示，约有1.3万人在巴西参与了试验。试验结果显示，科兴疫苗超过国际科学家认为的提供保护所需要的50%有效性门槛。

不过，圣保罗州政府和布坦坦研究所表示，由于需要对临床试验数据做进一步分析，所以目前还无法公布具体的有效性数据。

The Butantan Institute didn't publish the results of those trials due to a clause in the Sinovac contract forbidding doing so until all global clinical trials are completed. In Brazil, 13,000 volunteers took part in the trials, which were also performed in Indonesia, Turkey and Chile. 

圣保罗州政府表示，计划于2021年1月25日开始在圣保罗州进行克尔来福新冠疫苗接种。

"Our entire program remains unchanged. The production of doses is continuing in our factory and the immunization campaign will begin as expected on January 25," said Sao Paulo Health Secretary Jean Gorinchteyn. 

推荐阅读：